Cutaneous pseudolymphoma following quadrivalent human papillomavirus vaccination – a rare adverse event

Pinheiro, Rita; Duarte, Bruno; João, Alexandre; Lencastre, André

doi:10.1111/ddg.13470

Cited by 5 publications

(9 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Drug-associated EM accounts for <10% of cases. 3 The drugs most commonly associated with EM are anti-epileptics, antibiotics (particularly cephalosporins and penicillin), anti-fungals and allopurinol. EM in the context of the MMR, Influenza, DPT and Hepatitis B vaccines has also been reported.…”

Section: Acknowledgementmentioning

confidence: 99%

“…2 Development of pseudolymphoma at the SARS-CoV-2 injection site is however previously undescribed. The acute or delayed occurrence of cutaneous pseudolymphoma has been reported at the injection site of Hepatitis A, Hepatitis B, 1 quadrivalent human papilloma virus, 3 early summer time meningoencephalitis and tetanus vaccination. papules, nodules and erythematous patches can be presenting signs of vaccine-associated cutaneous pseudolymphoma.…”

mentioning

confidence: 99%

See 1 more Smart Citation

SARS‐CoV‐2 mRNA vaccine injection site pseudolymphoma

Mintoff

Scerri

Betts

2021

Acad Dermatol Venereol

View full text Add to dashboard Cite

Section: Acknowledgementmentioning

confidence: 99%

mentioning

confidence: 99%

SARS‐CoV‐2 mRNA vaccine injection site pseudolymphoma

Mintoff

Scerri

Betts

2021

Acad Dermatol Venereol

View full text Add to dashboard Cite

“…While the exact pathogenesis of the disease remains unclear, recent studies suggest that drugs responsible for causing CPL can weaken immune function by interfering with immunosurveillance leading to abnormal lymphocyte proliferation, increased suppressor T‐cell activity and hypogammaglobulinaemia 8–14 …”

Section: Introductionmentioning

confidence: 99%

Drug‐induced cutaneous pseudolymphoma: A systematic review of the literature

et al. 2022

View full text Add to dashboard Cite

Drug‐induced cutaneous pseudolymphoma (CPL) is a common form of pseudolymphoma and there are numerous drugs associated with it. In this study, we performed a systematic review of the literature by searching PubMed/Medline and Embase databases to determine the most common drugs responsible for CPL and to define the demographic, clinical, histopathological and immunopathological characteristics of patients (updated on 30 December 2020). From 883 initially found articles, 56 studies (89 reported cases) were included. The mean age of patients was 54.4 ± 17.7 (ranging 8–86) years, and 46 (51.7%) were men. The median time interval between drug intake and CPL occurrence was 120 days (range 1–7300 days). The shortest median time interval between taking the drug and the onset of the disease was observed among patients taking antidepressants (60 days) (range 7–540) and the longest median time interval was observed in individuals using immunomodulators (300 days) (range 3–7300). The most‐reported drug categories causing CPL were anti‐hypertensives (17.9%), anticonvulsants (14.6%), monoclonal antibodies (13.4%) and antidepressants (11.2%). Moreover, the most common drugs were phenytoin (6.7%), amlodipine (5.6%), fluoxetine (5.6%) and carbamazepine (4.4%). Histopathological evaluation of 76 cases revealed 62 (81.5%) reports of T‐cell infiltrations. Furthermore, positive reports of CD4 (94.0%), CD8 (93.0%) and CD30 (87.5%) were noted. The lowest prevalence of CD30‐positive reports was observed among monoclonal antibodies. In conclusion, anti‐hypertensives, anti‐convulsants, monoclonal antibodies and anti‐depressants are the most common drugs responsible for CPL. It mostly presents in middle‐aged patients with almost no gender difference as pruritic papules, nodules and plaques.

show abstract

“…Isolated cases of pseudolymphoma resembling cutaneous lymphoid hyperplasia (CLH) at the injection site have also been reported in the context of several vaccinations in including those against COVID‐19, 36 hepatitis A and hepatitis B, 37,38 early summer meningoencephalitis, 38 tetanus, 38 quadrivalent human papillomavirus, 39 and influenza 40 . A causative role for aluminum hydroxide in the development of CLH‐type injection site reactions has been suggested 37 .…”

Section: Discussionmentioning

confidence: 99%

Two cases of challenging cutaneous lymphoid infiltrates presenting in the context of COVID‐19 vaccination: A reactive lymphomatoid papulosis‐like eruption and a bona fide lymphoma

et al. 2022

View full text Add to dashboard Cite

COVID‐19 infection and vaccination may be associated with a wide variety of cutaneous and immune manifestations. Here, we describe two patients who presented with monoclonal cutaneous T‐cell infiltrates that showed cytologic and immunophenotypic features concerning for lymphoma shortly following COVID‐19 vaccination. In one case, the eruption completely resolved. The second patient showed initial resolution, but her disease recurred and progressed following a breakthrough SARS‐CoV‐2 infection. These cases suggest that immune stimulation following exposure to SARS‐Cov‐2 protein(s) in vaccine or infection may facilitate the development of a lymphoma or lymphoproliferative disorder in susceptible individuals. Moreover, they show that separating these cases from pseudolymphomatous reactive conditions is often challenging and requires close clinical correlation.

show abstract

Cutaneous pseudolymphoma following quadrivalent human papillomavirus vaccination – a rare adverse event

Cited by 5 publications

References 7 publications

SARS‐CoV‐2 mRNA vaccine injection site pseudolymphoma

SARS‐CoV‐2 mRNA vaccine injection site pseudolymphoma

Drug‐induced cutaneous pseudolymphoma: A systematic review of the literature

Two cases of challenging cutaneous lymphoid infiltrates presenting in the context of COVID‐19 vaccination: A reactive lymphomatoid papulosis‐like eruption and a bona fide lymphoma

Contact Info

Product

Resources

About